Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now0:00
0:00
Loading audio file, please wait.
ImmuneWorks has received a $300,000 investment from Indiana Seed Fund I to help the Indianapolis company research a manufacturing process for a drug it is developing to fight idiopathic pulmonary fibrosis, a lung disease.
The fund is managed by BioCrossroads, the not-for-profit that promotes the life sciences industry in the state.
Founded last year by Dr. David Wilkes and other Indiana University School of Medicine researchers, ImmuneWorks also is developing blood tests to diagnose the disease and track patient progress while the disease is being treated.
Please enable JavaScript to view this content.